Skip to main content
logo
Baxter International Inc. (BAX)
NYSE: BAX · Real-Time Price · USD
18.91
+0.25 (1.34%)
At close: Nov 26, 2025, 4:00 PM EST
18.95
+0.04 (0.21%)
After-hours: Nov 26, 2025, 7:54 PM EST

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
United States Revenue
6.08B5.85B
Log In
Log In
Log In
Upgrade
Emerging Markets Revenue
1.35B1.35B
Log In
Log In
Log In
Upgrade
Rest of World Revenue
3.60B3.44B
Log In
Log In
Log In
Upgrade
Revenue (Total)
11.02B10.64B
Log In
Log In
Log In
Upgrade

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Americas Revenue
--
Log In
Log In
Log In
Upgrade
EMEA Revenue
--
Log In
Log In
Log In
Upgrade
APAC Revenue
--
Log In
Log In
Log In
Upgrade
Hillrom Revenue
--
Log In
Log In
Log In
Upgrade
Revenue (Total)
11.02B10.64B
Log In
Log In
Log In
Upgrade

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Medication Delivery Revenue
--
Log In
Log In
Log In
Upgrade
Clinical Nutrition Revenue
--
Log In
Log In
Log In
Upgrade
Infusion Therapies Revenue
4.06B4.10B
Log In
Log In
Log In
Upgrade
Advanced Surgery Revenue
1.16B1.10B
Log In
Log In
Log In
Upgrade
Medical Products & Therapies Revenue
5.23B5.21B
Log In
Log In
Log In
Upgrade
Patient Support Systems Revenue
--
Log In
Log In
Log In
Upgrade
Surgical Solutions Revenue
--
Log In
Log In
Log In
Upgrade
Care & Connectivity Solutions Revenue
1.88B1.81B
Log In
Log In
Log In
Upgrade
Front Line Care Revenue
1.15B1.14B
Log In
Log In
Log In
Upgrade
Healthcare Systems & Technologies Revenue
3.03B2.95B
Log In
Log In
Log In
Upgrade
Injectables and Anesthesia Revenue
1.38B1.37B
Log In
Log In
Log In
Upgrade
Drug Compounding Revenue
1.09B1.04B
Log In
Log In
Log In
Upgrade
Pharmaceuticals Revenue
2.47B2.41B
Log In
Log In
Log In
Upgrade
Chronic Therapies Revenue
--
Log In
Log In
Log In
Upgrade
Acute Therapies Revenue
--
Log In
Log In
Log In
Upgrade
Kidney Care Revenue
--
Log In
Log In
Log In
Upgrade
Other Revenue (Post-Q2 2023 Reporting)
302.00M67.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
11.02B10.64B
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
BioPharma Solutions Revenue
--
Log In
Log In
Log In
Upgrade
Other Revenue (Pre-Q3 2023 Reporting)
--
Log In
Log In
Log In
Upgrade
Revenue (Total)
11.02B10.64B
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Medical Products & Therapies Operating Income
973.00M950.00M
Log In
Log In
Log In
Upgrade
Healthcare Systems & Technologies Operating Income
460.00M468.00M
Log In
Log In
Log In
Upgrade
Pharmaceuticals Operating Income
285.00M313.00M
Log In
Log In
Log In
Upgrade
Kidney Care Operating Income
--
Log In
Log In
Log In
Upgrade
Other Operating Income
23.00M18.00M
Log In
Log In
Log In
Upgrade
Operating Income (Total)
-14.00M14.00M
Log In
Log In
Log In
Upgrade

EBIT by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212011 - 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2011 - 2020
Americas Operating Income
--
Log In
Log In
Log In
Upgrade
EMEA Operating Income
--
Log In
Log In
Log In
Upgrade
APAC Operating Income
--
Log In
Log In
Log In
Upgrade
Hillrom Operating Income
--
Log In
Log In
Log In
Upgrade
Operating Income (Total)
-14.00M14.00M
Log In
Log In
Log In
Upgrade
Updated Oct 30, 2025. Data Source: Fiscal.ai.